Targeted next-generation sequencing has become a critical tool for the interrogation of genomic events in myeloid malignancies. In this webinar, Dr. Eric Padron of the Moffitt Cancer Center, discussed his experience using the RainDance ThunderBolts Myeloid panel focusing on his experience with the library preparation and sequencing results on the MiSeq instrument. This presentation was given from the perspective of a translational laboratory rather than that of a large genomics core or commercial enterprise.
Dr. Padron is an Assistant Member in the Immunology Program and Malignant Hematology Department of the Moffitt Cancer Center. After completing his undergraduate, medical school, and residency at the University of Florida, he moved to Moffitt Cancer Center where he completed a Hematology and Oncology Fellowship. Dr. Padron’s current general research interests are focused on understanding the genetic pathobiology of CMML, using primary patient samples to understand the clinical implementation of genomics and to generate novel therapies in CMML and other myeloid malignancies.
About the Co-presenter
Jeff Olson is the Director of Genomic Applications at RainDance Technologies. He holds a degree in Biology from the Massachusetts Institute of Technology. His career has been focused on developing new technologies, platforms and assays for molecular biology applications. Jeff has worked in the Biotechnology industry for 30+ years, including experience ranging from early stage startup companies to large pharmaceutical companies.